<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880840</url>
  </required_header>
  <id_info>
    <org_study_id>MP 442</org_study_id>
    <nct_id>NCT01880840</nct_id>
  </id_info>
  <brief_title>Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages &gt;6 Months to &lt;6 Years With AR</brief_title>
  <official_title>Randomized Trial of the Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages &gt;6 Months to &lt;6 Years With Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novella Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Meda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety of 2 different doses of the
      investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of
      allergic rhinitis (AR). This is an open-label study; that is, parent and child will know
      which group each is in.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 200 subjects, between the ages of ≥ 6 months to &lt; 6 years of age who have a
      history of AR will participate in this study.

      The study will be conducted at about 20 research centers in the United States. Each research
      center will enroll approximately 2 to 10 subjects.

      The study will involve at least 4 office visits over at least a 4-week period. You will need
      to keep the appointments as scheduled by the study personnel.

      Some medications or therapies could interfere with the safety evaluations conducted in this
      study. If your child is currently taking any of these medications or therapies, they will
      need to discontinue them in order to be eligible for this study. Your study doctor will
      discuss this with you along with information on how this could affect your child's health. If
      you and the study doctor decide this is appropriate, there is a specific time period that
      these will need to be discontinued before your child can proceed in study evaluation.

      If your child is eligible for study participation, he/she will be randomly assigned (by
      chance, like the flip of a coin) to one of the following two study drug groups:

        -  Astepro (azelastine hydrochloride) 0.15% Nasal Spray, 822 mcg (total daily dose); OR

        -  Astepro (azelastine hydrochloride) 0.1% Nasal Spray, 548 mcg (total daily dose)

      The following are being performed for the purposes of this study and are not considered
      standard care:

        -  Your child will be placed in one of the two study drug groups by chance.

        -  You will complete questionnaires about your child's allergy symptoms.

        -  You will complete diary cards each morning recording your child's allergy symptoms over
           the previous 24 hours.

        -  Your child will have his/her vital signs measured (blood pressure, pulse, temperature
           and breathing rate).

        -  You and your child will be asked questions regarding your child's use of any medication
           or supplements and how your child has felt since his/her last visit.

        -  Blood and urine samples will be collected to assess the safety of taking the study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>one month of treatment</time_frame>
    <description>The objective of this clinical trial is to evaluate the safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray at a dosage of 1 spray per nostril twice daily in subjects ≥6months to &lt;6 years of age with allergic rhinitis.
Safety will be assessed on the basis of reported adverse experiences, nasal examinations, laboratory evaluations, and vital signs assessments.
Data for each age strata will be summarized separately as well as combined.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Astepro 0.15% Nasal Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal Spray at a dosage of 1 spray per nostril twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Astepro 0.1% Nasal Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal Spray at a dosage of 1 spray per nostril twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>205.5 mcg of azelastine hydrochloride</intervention_name>
    <description>nasal spray</description>
    <arm_group_label>Astepro 0.15% Nasal Spray</arm_group_label>
    <other_name>astepro .15%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>137 mcg of azelastine hydrochloride</intervention_name>
    <description>nasal spray</description>
    <arm_group_label>Astepro 0.1% Nasal Spray</arm_group_label>
    <other_name>astepro .1%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects &gt;6 months to &lt;6 years, inclusive at the screening visit

          -  A history of AR

          -  The parent must provide written informed consent and the child must provide assent, if
             possible

          -  Willing and able to comply with the study requirements

          -  May benefit from treatment with Astepro Nasal Spray, based on the Investigator's
             assessment (based on medical history, physical examination, etc.) of the subject's
             clinical condition, at both the Screening and Randomization Visits

          -  General good health and free of any disease or concomitant treatment that could
             interfere with the interpretation of the study results as determined by the
             investigator or the sponsor's medical officer

          -  Subjects receiving immunotherapy injections (antigen desensitization) must be on a
             stable maintenance regimen for at least 30 days before the first study visit
             (adjustments to regimen following a brief period of missed injections do not preclude
             participation)

        Exclusion Criteria:

          -  On nasal examination, subjects with superficial nasal mucosal erosion, moderate nasal
             mucosal erosion, nasal mucosal ulceration, nasal septum perforation

          -  Other nasal disease(s) likely to affect deposition of intranasal medication, such as
             acute sinusitis, rhinitis medicamentosa or clinically significant polyposis or nasal
             structural abnormalities

          -  Nasal surgery or sinus surgery within the previous year

          -  Chronic sinusitis

          -  The use of any investigational drug within 30 days prior to Visit 1. No
             investigational products are permitted for use during the conduct of this study

          -  Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol
             or sucralose (Splenda® brand sweetener)

          -  Respiratory tract infections within two weeks prior to Visit 1.

          -  Subjects with significant pulmonary disease including asthma. Subjects with
             intermittent asthma who only require short-acting inhaled bronchodilators are eligible
             for enrollment. Asthma (with the exception of intermittent asthma). Subjects with
             intermittent asthma who only require short-acting inhaled bronchodilators (not more
             often than twice per week) and who do not have nocturnal awakening as a result of
             asthma are eligible for enrollment

          -  Chronic obstructive sleep apnea syndrome (clinical diagnosis)

          -  Existence of any surgical or medical condition, which in the opinion of the
             investigator or sponsor's medical monitor, might significantly alter the absorption,
             distribution, metabolism, or excretion of study drug or that might significantly
             affect the subject's ability to complete this trial

          -  Clinically relevant abnormal physical findings or laboratory results which, in the
             opinion of the investigator, would interfere with the objectives -- Family members of
             research center or private practice personnel who are directly involved in this study
             are excluded

          -  Members of the same family cannot enroll in the study at the same time.

          -  Subjects who have used medications or therapies that could interfere with safety
             evaluations (see Section 4.0)

          -  Any behavioral condition which could affect subject's ability to accurately report
             symptoms to the caregiver such as developmental delay, attention deficit disorder, and
             autism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Center of Alabama,LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Rock Allergy and Asthma Clinical research Center</name>
      <address>
        <city>Little Rock</city>
        <state>Alaska</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Storms Clinical Research Institute</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze and Itch Associates</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma &amp; Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Allergy, Asthna &amp; Urticaria Centers of Charleston Pa</name>
      <address>
        <city>Charleston</city>
        <state>Pennsylvania</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Allergy Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul H Ratner,MD</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Live Oak Allergy and Asthma Clinic</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Allergy,Asthma and Immunology/Allergy&amp; Asthma care of Waco</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <results_first_submitted>June 9, 2015</results_first_submitted>
  <results_first_submitted_qc>June 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 29, 2015</results_first_posted>
  <last_update_submitted>June 9, 2015</last_update_submitted>
  <last_update_submitted_qc>June 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Astepro 0.15%</title>
          <description>azelastine hydrochloride 822mcg nasal spray</description>
        </group>
        <group group_id="P2">
          <title>Astepro 0.1%</title>
          <description>azelastine hydrochloride 548 mcg nasal spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Astepro 0.15% Nasal Spray</title>
          <description>Nasal Spray at a dosage of 1 spray per nostril twice daily
205.5 mcg of azelastine hydrochloride: nasal spray</description>
        </group>
        <group group_id="B2">
          <title>Astepro 0.1% Nasal Spray</title>
          <description>Nasal Spray at a dosage of 1 spray per nostril twice daily
137 mcg of azelastine hydrochloride: nasal spray</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="191"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.29" spread="1.538"/>
                    <measurement group_id="B2" value="3.37" spread="1.595"/>
                    <measurement group_id="B3" value="3.33" spread="1.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety</title>
        <description>The objective of this clinical trial is to evaluate the safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray at a dosage of 1 spray per nostril twice daily in subjects ≥6months to &lt;6 years of age with allergic rhinitis.
Safety will be assessed on the basis of reported adverse experiences, nasal examinations, laboratory evaluations, and vital signs assessments.
Data for each age strata will be summarized separately as well as combined.</description>
        <time_frame>one month of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Astepro 0.15% Nasal Spray</title>
            <description>Nasal Spray at a dosage of 1 spray per nostril twice daily
205.5 mcg of azelastine hydrochloride: nasal spray</description>
          </group>
          <group group_id="O2">
            <title>Astepro 0.1% Nasal Spray</title>
            <description>Nasal Spray at a dosage of 1 spray per nostril twice daily
137 mcg of azelastine hydrochloride: nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>The objective of this clinical trial is to evaluate the safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray at a dosage of 1 spray per nostril twice daily in subjects ≥6months to &lt;6 years of age with allergic rhinitis.
Safety will be assessed on the basis of reported adverse experiences, nasal examinations, laboratory evaluations, and vital signs assessments.
Data for each age strata will be summarized separately as well as combined.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Astepro 0.15% Nasal Spray</title>
          <description>Nasal Spray at a dosage of 1 spray per nostril twice daily
205.5 mcg of azelastine hydrochloride: nasal spray</description>
        </group>
        <group group_id="E2">
          <title>Astepro 0.1% Nasal Spray</title>
          <description>Nasal Spray at a dosage of 1 spray per nostril twice daily
137 mcg of azelastine hydrochloride: nasal spray</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>exacerbation of asthma</sub_title>
                <description>recovered/resolved</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dysgusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>oropharyngial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>sneezing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatitis,contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Nancy Ruiz Chief Medical Officer</name_or_title>
      <organization>Meda Pharmaceutical</organization>
      <phone>732 564 2200 ext 2390</phone>
      <email>nancy.ruiz@meda.us</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

